Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
114 hedge funds and large institutions have $294M invested in Achillion Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 31 reducing their positions, and 10 closing their positions.
89% more call options, than puts
Call options by funds: $291K | Put options by funds: $154K
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
4% more funds holding
Funds holding: 110 → 114 (+4)
10% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 31
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.28% less ownership
Funds ownership: 79.42% → 79.14% (-0.28%)
10% less capital invested
Capital invested by funds: $326M → $294M (-$31.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
+$8.6M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$5.39M |
| 3 |
BCPEMI
Bain Capital Public Equity Management II
Boston,
Massachusetts
|
+$3.72M |
| 4 |
Morgan Stanley
New York
|
+$2.25M |
| 5 |
Renaissance Technologies
New York
|
+$2.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$7.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.88M |
| 3 |
Millennium Management
New York
|
-$2.41M |
| 4 |
Goldman Sachs
New York
|
-$1.73M |
| 5 |
Axa
Paris,
France
|
-$1.67M |
ACHN Hedge Fund Activity: Q2 2019 in Review
114 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q2 2019, worth a combined $294M — down 9.8% from $326M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ACHN positions and 10 closed out — a net gain of 7 holders — while 34 added to existing stakes and 31 trimmed.
The largest buyer was Nuveen, opening a new position worth an estimated $8.6M. The largest seller was Armistice Capital, exiting entirely with an estimated $7.4M sold.
- 114 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q2 2019, up from 110 in Q1 2019.
- Funds reported $294M of Achillion Pharmaceuticals stock for Q2 2019, down 9.8% quarter-over-quarter.
- 17 funds opened new Achillion Pharmaceuticals positions in Q2 2019 and 10 closed out, a net change of +7 holders.
- The largest Achillion Pharmaceuticals buyer in Q2 2019 was Nuveen, an estimated $8.6M added.
- The largest Achillion Pharmaceuticals seller in Q2 2019 was Armistice Capital, an estimated $7.4M sold.
Based on aggregated 13F filings for Q2 2019.